NasdaqGM - Nasdaq Real Time Price USD

Wave Life Sciences Ltd. (WVE)

Compare

13.45

+0.01

(+0.07%)

At close: December 16 at 4:00:01 PM EST

14.15

+0.70

(+5.20%)

After hours: December 16 at 6:27:01 PM EST

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET. A live webcast of this presentation can be a

GlobeNewswire 14 hours ago

WVE
+0.07%
Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December. 7ᵗʰ Annual Evercore HealthCONx ConferenceDate: Tuesday, December 3, 2024Analyst-led fireside chat: 3:00 p.m. ET Citi 2024 Glob

GlobeNewswire 20 days ago

WVE
+0.07%
Wave Life Sciences to Present at Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET. A live webcast of this presenta

GlobeNewswire last month

WVE
+0.07%
Wave Life Sciences Ltd. (NASDAQ:WVE) Released Earnings Last Week And Analysts Lifted Their Price Target To US$22.20

Wave Life Sciences Ltd. ( NASDAQ:WVE ) missed earnings with its latest third-quarter results, disappointing...

Simply Wall St. last month

WVE
+0.07%
Wave Life Sciences Third Quarter 2024 Earnings: Misses Expectations

Wave Life Sciences ( NASDAQ:WVE ) Third Quarter 2024 Results Key Financial Results Net loss: US$61.8m (down from...

Simply Wall St. last month

WVE
+0.07%
WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Despite a net loss, WAVE Life Sciences Ltd (WVE) showcases promising clinical progress and a strengthened financial position to support future growth.

GuruFocus.com last month

WVE
+0.07%
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -67.86% and 149.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

WVE
+0.07%
Wave Life Sciences: Q3 Earnings Snapshot

SINGAPORE (AP) — Wave Life Sciences Pte. Ltd. (WVE) on Tuesday reported a loss of $61.8 million in its third quarter. On a per-share basis, the Singapore-based company said it had a loss of 47 cents.

Associated Press Finance last month

WVE
+0.07%
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following

GlobeNewswire last month

WVE
+0.07%
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?

Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

WVE
+0.07%
YMAB
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company’s third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section

GlobeNewswire last month

WVE
+0.07%
Institutional investors in Wave Life Sciences Ltd. (NASDAQ:WVE) see US$94m decrease in market cap last week, although long-term gains have benefitted them.

Key Insights Significantly high institutional ownership implies Wave Life Sciences' stock price is sensitive to their...

Simply Wall St. last month

WVE
+0.07%
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Recent proof-of-mechanism data for WVE-006 unlocked Wave’s best-in-class RNA editing capabilities; three new wholly owned RNA editing programs targeting PNPLA3, LDLR and APOB are first-in-class approaches to address si

GlobeNewswire last month

WVE
+0.07%
How to play biotech stocks: Insmed and Wave Life Sciences

There are opportunities for investors in the healthcare sector, but it lies with the small-cap biotech companies, not big pharma, Stacey Sears, the Emerald Growth Fund (HSPGX) portfolio manager at Emerald Advisers, says. Sears sits down with Julie Hyman and Josh Lipton on Market Domination to discuss how to play biotech stocks. “If you think about advancements in DNA editing, advancements in RNA editing, which are ongoing as we sit here today, and broader pursuit of orphan and rare diseases. Decoding of the genome has really enabled that, and small caps have been a big player in that. As a matter of fact, if you take a look at 2023, approximately two-thirds of clinical trials were started by companies in the small and emerging biotechnology space, and approximately 56% of the new drug substances approved in 2023 originated within small and emerging biotechnology companies,” Sears tells Yahoo Finance. The portfolio manager explains, “Valuation has always been more challenging within the healthcare area, but I would say what is now a tailwind is that the sector has been underperforming over the last couple of years," given its inverse performance with interest rates. Sears highlights Insmed (INSM) and Wave Life Sciences (WVE) as small-cap biotech names that are poised to gain. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.

Yahoo Finance Video last month

WVE
+0.07%
INSM
Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Wave Life Sciences (WVE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks last month

WVE
+0.07%
1 Brand-New Big Reason to Buy This Biotech Stock Right Now

This stock currently has a good balance of risk and potential rewards.

Motley Fool last month

WVE
+0.07%
What Makes Wave Life Sciences (WVE) a Strong Momentum Stock: Buy Now?

Does Wave Life Sciences (WVE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks last month

WVE
+0.07%
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.

Shares of Korro Bio and Wave Life Sciences diverged Monday after an analyst argued Korro is the better way to play the RNA-editing space.

Investor's Business Daily last month

KRRO

GLAXF

GSK
Wave Life Sciences Shares Surge After RNA Editing Discovery

Innovative achievement that can shift how genetics diseases are treated

GuruFocus.com last month

WVE
+0.07%
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data

Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD.

Zacks last month

WVE
+0.07%

Performance Overview

Return	WVE	S&P 500
YTD	+166.34%	+27.34%
1-Year	+204.99%	+28.71%
3-Year	+297.93%	+28.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Wave Life Sciences Ltd. (WVE)

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Wave Life Sciences to Present at Upcoming Investor Conferences

Wave Life Sciences to Present at Jefferies London Healthcare Conference

Wave Life Sciences Ltd. (NASDAQ:WVE) Released Earnings Last Week And Analysts Lifted Their Price Target To US$22.20

Wave Life Sciences Third Quarter 2024 Earnings: Misses Expectations

WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates

Wave Life Sciences: Q3 Earnings Snapshot

Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

Institutional investors in Wave Life Sciences Ltd. (NASDAQ:WVE) see US$94m decrease in market cap last week, although long-term gains have benefitted them.

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

How to play biotech stocks: Insmed and Wave Life Sciences

Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know

1 Brand-New Big Reason to Buy This Biotech Stock Right Now

What Makes Wave Life Sciences (WVE) a Strong Momentum Stock: Buy Now?

Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.

Wave Life Sciences Shares Surge After RNA Editing Discovery

WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data

Performance Overview